Thalidomide in Treating Patients With Myelodysplastic Syndrome

NCT00015990 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

29

Enrollment

NIH

Sponsor class

Conditions

Chronic Myelomonocytic Leukemia
de Novo Myelodysplastic Syndromes
Previously Treated Myelodysplastic Syndromes
Refractory Anemia
Refractory Anemia With Excess Blasts
Refractory Anemia With Excess Blasts in Transformation
Refractory Anemia With Ringed Sideroblasts
Secondary Myelodysplastic Syndromes

Interventions

DRUG: thalidomide
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)